Paper Review Records
全部论文审稿周期
15 篇有效样本 · 按发表日期由新到旧排列
审稿天数=录用日期-收稿日期;保留 PDF/DOI/网页源链接
71
天
Real-World Assessment of Prophylactic Anakinra on Neurotoxicity and Cytokine Release Syndrome after CD19 Chimeric Antigen Receptor T-Cell Therapy in Relapsed and Refractory B-Cell Lymphoma: An Inverse Probability of Treatment Weighting Analysis
作者
Neela Easton; Mia Andreoli; Herman van Besien; Caitlin Gribbin; Michelle Pasciolla; Anna Alperovich; Mateo Mejia Saldarriaga; Barbara Ma; Nora Chokr; Amer Assal; Joshua Fein; Sebastian Mayer; Alexandra Gomez Arteaga; Daniel Choi; Tsiporah Shore; Christopher S. Hackett; Juliet Barker; Samuel Yamshon展开收起
作者单位
NewYork-Presbyterian/Weill Cornell, Hematology & Medical Oncology, New York, New York; NewYork-Presbyterian/Weill Cornell Medical Center, Medicine, New York, New York; Perlmutter Cancer Center, NYU Langone, New York, New York展开收起
12
天
79
天
Comparative Evaluation of Single-Dose and Split-Dose Melphalan Conditioning Concerning Toxicity Profiles and Engraftment Kinetics: A Propensity Score-Matched Analysis
作者
Ceren Uzunoğlu Güren; Derya Demirtaş; Ezel Elgün; Tuğçe Bulun; Elif Suyanı; Bilal Aygün; Didar Yanardağ Açık; Fahir Özkalemkaş; Vildan Özkocaman; Asu Fergün Yılmaz; Ayşe Tülin Tuğlular; Işık Atagündüz; Tayfur Toptaş展开收起
作者单位
Department of Hematology, Marmara University Hospital, Istanbul, Turkey; Department of Hematology, Adana City Training and Research Hospital, Adana, Turkey; Department of Hematology, Bursa Uludağ University, Bursa, Turkey; Department of Hematology, Acibadem Fulya Hospital, Istanbul, Turkey展开收起
48
天
Outcomes and Safety of CAR-T Cell Therapy in B-NHL Patients With Reduced Left Ventricular Ejection Fraction
作者
Alexandra E. Rojek; Jia Guo; Justin Kline; Satyajit Kosuri; Michael R. Bishop; Jeanne DeCara; Peter A. Riedell展开收起
作者单位
David and Etta Jonas Center for Cellular Therapy, University of Chicago, Chicago, Illinois; Section of Cardiology, Department of Medicine, University of Chicago, Chicago, Illinois展开收起
75
天
Impact of ASTCT Toxicity Grading System on Outcomes After CAR-T for Mature B-Cell Malignancies
作者
Marina Gomez-Llobell; Silvia Escribano Serrat; Maria Bromberg; Venkatraman Seshan; Sean Devlin; Sigrun Einarsdottir; Ori Ben Valid; Noa Golan-Aceb; Ronit Marcus; Avichai Simoni; Ofrat Beyar-Katz; Shoshan Perek; Ali Abed Al Wahad; Magdalena Corona; Kai Rejeski; Sandeep S. Raj; Parastoo Dahi; Michael Scordo; Gunjan L. Shah; M. Lia Palomba; Gilles Salles; Jae H. Park; Roni Shouval; Abraham Avigdor; Jaime Sanz; Miguel-Angel Perales展开收起
作者单位
Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Department of Medicine, Complutense University of Madrid, Madrid, Spain; Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York; Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, New York; Department of Medicine, Weill Cornell Medical College, New York, New York; Hematology and Bone Marrow Transplantation, Sheba Medical Center, Ramat Gan, Israel; Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel; Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa; The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel; Institute of Hematology, Lady Davis Carmel Medical Center, Haifa, Israel; Department of Medicine III – Hematology/Oncology, LMU University Hospital, LMU Munich, Munich, Germany; Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, New York; Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Hematology Department, Hospital Universitari i Politècnic La Fe, Departament de Medicina Universitat de Valencia, CIBERONC, Instituto Carlos III, Spain展开收起
55
天
Vaccine-Induced Anti-HBs Response is Associated with Protection Against Hepatitis B Virus Reactivation after Allogeneic Hematopoietic Cell Transplantation: A Randomized Trial
作者
Masahiro Onozawa; Shigeru Kusumoto; Yachiyo Kuwatsuka; Takayoshi Miyazono; Masatsugu Tanaka; Yuho Najima; Kohei Okada; Souichi Shiratori; Takayuki Sato; Junya Kanda; Yuichiro Inagaki; Tohru Murayama; Kaoru Hatano; Koichi Onodera; Masatoshi Sakurai; Shinya Endo; Takahiro Kumode; Hidehiro Itonaga; Yukiyoshi Moriuchi; Nobuhiro Kanemura; Tatsuya Imi; Taro Edahiro; Nobuaki Fukushima; Masahiro Oura; Shunsuke Yui; Mitsumasa Watanabe; Tomomi Toubai; Toshihiko Ando; Daisuke Nakamura; Masaharu Tamaki; Yasutaka Kakinoki; Takahiro Okada; Nobuaki Nakano; Takayoshi Tachibana; Hiroaki Shimizu; Shuichi Ota; Shinsuke Iida; Masaya Sugiyama; Yoshiko Atsuta; Takanori Teshima; Tomoharu Yoshizumi; Masashi Mizokami展开收起
作者单位
Department of Hematology, Hokkaido University Hospital, Sapporo, Japan; Department of Hematology and Cell therapy, Aichi Cancer Center, Nagoya, Japan; Department of Hematology and Oncology, Nagoya City University Hospital, Nagoya, Japan; Department of Advanced Medicine, Nagoya University Hospital, Nagoya, Japan; Department of Hematology, Imamura General Hospital, Kagoshima, Japan; Department of Hematology, Kanagawa Cancer Center, Yokohama, Japan; Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan; Department of Hematology, Sapporo Hokuyu Hospital, Sapporo, Japan; Department of Hematology/Oncology, Kurashiki Central Hospital, Kurashiki, Japan; Department of Hematology, Graduate School of Medicine, Kyoto University Hospital, Kyoto, Japan; Department of Hematology and Oncology, Anjo Kosei Hospital, Anjo, Japan; Department of Hematology, Hyogo Cancer Center, Akashi, Japan; Department of Medicine, Division of Hematology, Jichi Medical University, Shimotsuke, Japan; Department of Hematology, Tohoku University Hospital, Sendai, Japan; Department of Medicine, Division of Hematology, Keio University School of Medicine, Tokyo, Japan; Department of Hematology, Rheumatology and Infectious Diseases, Kumamoto University Hospital, Kumamoto, Japan; Hematology and Rheumatology, Kindai University, Osaka, Japan; Transfusion and Cell Therapy Unit, Nagasaki University Hospital, Nagasaki, Japan; Department of Hematology, Sasebo City General Hospital, Sasebo, Japan; Department of Hematology & Infectious Disease, Gifu University Hospital Gifu, Japan; Department of Hematology, Faculty of Medicine, Institute of Medical, Pharmaceutical, and Health Sciences, Kanazawa University, Kanazawa, Japan; Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan; Department of Hematology and Oncology, Konan Kosei Hospital, Konan, Japan; Department of Hematology, Endocrinology and Metabolism, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan; Department of Hematology, Nippon Medical School, Tokyo, Japan; Department of Hematology, Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Japan; Department of Hematology and Cell Therapy, Yamagata University Hospital, Yamagata, Japan; Department of Internal Medicine, Division of Hematology, Respiratory Medicine and Oncology, Faculty of Medicine, Saga University, Saga, Japan; Department of Hematology and Rheumatology, Kagoshima University Hospital, Kagoshima, Japan; Division of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan; Department of Hematology, Asahikawa City Hospital, Asahikawa, Japan; Department of Hematology, Shimane University Hospital, Izumo, Japan; Department of Viral Pathogenesis and Controls, National Institute of Global Health and Medicine, Japan Institute for Health Security, Kohnodai, Japan; Japanese Data Center for Hematopoietic Cell Transplantation, Nagakute, Japan; Department of Registry Science for Transplant and Cellular Therapy, Aichi Medical University School of Medicine, Nagakute, Japan; Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; Genome Medical Sciences Project, National Institute of Global Health and Medicine, Japan Institute for Health Security, Konodai, Japan; Molecular and Cellular Glycoproteomics Research Group, Cellular and Molecular Biotechnology Research Institute, National Institute of Advanced Industrial Science and Technology, Tsukuba, Japan展开收起
FAQ
Transplantation and Cellular Therapy审稿要多久?
截至2026-11-13,CrushSCI 收录了 Transplantation and Cellular Therapy 的 15 篇完整审稿记录。最快一篇从收稿到录用用了 12 天(T-Cell Lymphoma Associated With CAR-T Cell Therapy: A Bayesian Disproportionality Analysis of a National Database,2026-05-28 收稿,2026-06-09 录用),最慢一篇用了 238 天;平均 68.9 天,中位数 55 天。
Expert Matching · Case Demo
把投稿要求,转成可验证的期刊方案
说清专业、时限和作者背景,CrushSCI 结合真实审稿样本,给出拟题方向、期刊初筛与周期判断。
